×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:NMTR

9 Meters Biopharma News Headlines

$0.21
-0.01 (-4.47%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.21
$0.24
50-Day Range
$0.21
$0.64
52-Week Range
$0.21
$1.46
Volume
10.12 million shs
Average Volume
6.71 million shs
Market Capitalization
$55.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

NMTR Media Mentions By Week

NMTR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NMTR
News Sentiment

0.29

0.80

Average
Medical
News Sentiment

NMTR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NMTR Articles
This Week

8

1

NMTR Articles
Average Week



NMTR Stock News Headlines Today

SourceHeadline
bizjournals.com logoRaleigh drugmaker shifts focus after trial setback
bizjournals.com - July 5 at 7:51 AM
MarketBeat logo9 Meters Biopharma (NASDAQ:NMTR) Downgraded by Maxim Group to Hold
americanbankingnews.com - July 2 at 6:32 AM
seekingalpha.com logo9 Meters stock falls despite drug showing promise in short bowel syndrome trial
seekingalpha.com - June 30 at 11:56 AM
seekingalpha.com logo9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drug
seekingalpha.com - June 30 at 11:56 AM
finance.yahoo.com logo9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
finance.yahoo.com - June 30 at 11:56 AM
finance.yahoo.com logo9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
finance.yahoo.com - June 30 at 11:56 AM
MarketBeat logo9 Meters Biopharma (NASDAQ:NMTR) Price Target Lowered to $3.00 at BMO Capital Markets
americanbankingnews.com - June 23 at 4:32 AM
finance.yahoo.com logoRaleigh pharma sees stock tumble after stopping trial. Now what?
finance.yahoo.com - June 22 at 7:14 AM
seekingalpha.com logo9 Meters stock slumps 54% as phase 3 Celiac disease trial of larazotide gets axed
seekingalpha.com - June 21 at 4:14 PM
finance.yahoo.com logoWhy Are 9 Meters Biopharma Shares Plunging Today?
finance.yahoo.com - June 21 at 4:14 PM
finance.yahoo.com logo9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
finance.yahoo.com - June 21 at 4:14 PM
finance.yahoo.com logo9 Meters Biopharma to Participate in the 2022 BIO International Convention
finance.yahoo.com - June 13 at 5:48 PM
finance.yahoo.com logo9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
finance.yahoo.com - May 19 at 6:41 PM
finance.yahoo.com logo9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
finance.yahoo.com - May 18 at 11:36 AM
finance.yahoo.com logo9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
finance.yahoo.com - May 16 at 9:01 AM
finance.yahoo.com logo9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
finance.yahoo.com - May 5 at 11:11 AM
seekingalpha.com logo9 meters Biopharma announces deal for Phase 3 trial of celiac disease treatment
seekingalpha.com - April 20 at 6:14 PM
finance.yahoo.com logo9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
finance.yahoo.com - April 20 at 1:13 PM
seekingalpha.com logo9 Meters Biopharma stock soars 19% on US patent for NM-136 to treat metabolic disorders
seekingalpha.com - April 13 at 1:36 PM
finance.yahoo.com logo9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
finance.yahoo.com - April 13 at 8:12 AM
morningstar.com logo9 Meters Biopharma Inc NMTR
morningstar.com - March 24 at 8:25 PM
benzinga.com logoRecap: 9 Meters Biopharma Q4 Earnings
benzinga.com - March 23 at 2:08 PM
finance.yahoo.com logo9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
finance.yahoo.com - March 23 at 7:26 AM
finance.yahoo.com logo9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
finance.yahoo.com - March 21 at 1:07 PM
finance.yahoo.com logo9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
finance.yahoo.com - March 9 at 8:37 AM
finance.yahoo.com logo9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
finance.yahoo.com - March 2 at 5:39 PM
finance.yahoo.com logo9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
finance.yahoo.com - February 28 at 7:49 PM
finance.yahoo.com logo9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
finance.yahoo.com - February 25 at 10:04 AM
finance.yahoo.com logo9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
finance.yahoo.com - February 9 at 11:17 AM
finance.yahoo.com logoParadigm, Strategies in Wealth Management, LLC Buys iShares iBonds Dec 2023 Term Corporate ETF, ...
finance.yahoo.com - February 8 at 2:53 PM
seekingalpha.com logo9 meters Bio secures new U.S. patent for NM-102 + immune checkpoint inhibitors
seekingalpha.com - January 24 at 10:02 AM
finance.yahoo.com logo9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
finance.yahoo.com - January 24 at 10:02 AM
finance.yahoo.com logoRaleigh public company adds former Biogen exec to C-suite
finance.yahoo.com - January 21 at 2:48 PM
finance.yahoo.com logo9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
finance.yahoo.com - January 18 at 2:14 PM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
finance.yahoo.com - January 4 at 1:36 PM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
finance.yahoo.com - January 4 at 1:36 PM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
finance.yahoo.com - January 4 at 7:50 AM
finance.yahoo.com logo9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
finance.yahoo.com - January 3 at 7:49 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
finance.yahoo.com - December 15 at 10:07 AM
finance.yahoo.com logoDown 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)
finance.yahoo.com - November 18 at 2:33 PM
finance.yahoo.com logo9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
finance.yahoo.com - November 15 at 8:50 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
finance.yahoo.com - November 10 at 7:50 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
finance.yahoo.com - November 9 at 7:57 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
finance.yahoo.com - October 26 at 7:51 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
finance.yahoo.com - October 19 at 8:50 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
finance.yahoo.com - October 4 at 9:16 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
finance.yahoo.com - September 27 at 8:56 AM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 22 at 12:15 PM
finance.yahoo.com logo9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 15 at 8:47 AM
nasdaq.com logoThursday 9/9 Insider Buying Report: TDG, NMTR
nasdaq.com - September 9 at 4:15 PM
Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:NMTR) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.